BioRestorative Therapies
40 Marcus Drive
Suite one
Melville, Long Island
New York
11747
United States
Tel: 6317608405
Website: http://www.biorestorative.com/
Email: hr@BIORESTORATIVE.COM
149 articles about BioRestorative Therapies
-
BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem® Program
8/31/2021
BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japanese Patent Office has issued the Company a patent related to its metabolic ThermoStem® Program.
-
BioRestorative Therapies Awarded One of Top 10 Spine Device Companies by MedTech Outlook
8/19/2021
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it has been named one of the Top 10 Spine Device Companies and featured by MedTech Outlook, a leading print and digital magazine that provides details and insights regarding novel and high impact medical technologies.
-
BioRestorative Therapies Discusses Upcoming Annual Meeting of Stockholders
8/11/2021
BioRestorative Therapies, Inc. today reminded its stockholders that its annual meeting of stockholders will be held on Tuesday, August 17, 2021 at 10 a.m. EDT.
-
BioRestorative Therapies Announces Filing of Registration Statement for Proposed Public Offering
8/9/2021
BioRestorative Therapies, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed underwritten public offering of its securities.
-
BioRestorative Therapies to Present at the Emerging Growth Conference on June 9, 2021
6/7/2021
BioRestorative Therapies invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the online Emerging Growth Conference.
-
BioRestorative Therapies Expanding its Cell Therapy Manufacturing Facility
5/10/2021
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it is initiating expansion of its Melville, New York based research laboratories to include capabilities for the clinical production of the Company’s pipeline of clinical and investigational cell therapy candidates.
-
BioRestorative Therapies Announces Compliance with SEC Reporting Requirements and “Stop Sign” Removal
5/3/2021
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2020 and, as a result, is now current in its SEC periodic filings.
-
BioRestorative Therapies Announces Appointment of Nickolay V. Kukekov, Ph.D to its Board of Directors
4/5/2021
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced the appointment of Nickolay V. Kukekov to the BioRestorative Board of Directors, effective March 18th, 2021.
-
BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem® ProgramNotice of Allowance Grants Protection for Deriving Exosomes from Brown Adipocytes
3/31/2021
BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX) , a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem ® Program. The notice of allowance was issued on March 22, 2021 and is related to a new patent application not previously announced.
-
BioRestorative Therapies Announces Notices of Allowance for Three Patent Applications for its Off-the-Shelf ThermoStem® Program
3/22/2021
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that the United States Patent Office and several International agencies have issued notices of allowance for three separate patent applications related to the Company’s metabolic ThermoStem® Program.
-
BioRestorative Therapies Announces Filing of 2019 Annual Report on Form 10-K
3/18/2021
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2019 with the U.S. Securities and Exchange Commission. A copy of the annual report is available on BioRestorative Therapies website, www.biorestorative.com, by selecting “Investors” and then “SEC Filings”.
-
BioRestorative Therapies Provides End of Year Shareholder LetterCompany Expects Several Milestones as Momentum Builds for 2021
1/5/2021
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced the following letter from its Chief Executive Officer, Lance Alstodt, to its shareholders and the investment community.
-
BioRestorative Therapies Emerges from Chapter 11 Reorganization
11/20/2020
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that its amended joint plan of reorganization has become effective and it has emerged from Chapter 11 reorganization.
-
BioRestorative Therapies Featured in IEEE Pulse Magazine’s Cover Story About Stem Cell Therapies for Low Back Pain
12/16/2019
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today feature coverage in the news outlet, IEEE Pulse, a magazine of the IEEE Engineering in Medicine and Biology Society.
-
BioRestorative Therapies Receives Patent in Israel For Its Metabolic Program
12/12/2019
This is the eighth patent issued, in the United States and other countries, for the Company’s brown fat technology related to BioRestorative’s metabolic program
-
BioRestorative Therapies Receives A Second Patent in Australia For Its Metabolic Program
10/23/2019
This patent will allow for the protection of a specific isolated human brown adipose tissue stem cell line capable of differentiating into multiple cell types.
-
BioRestorative Therapies Announces the Appointment of Adam D. Bergstein as Sr. VP, Planning and Business Development
1/22/2018
In this capacity, Mr. Bergstein will be responsible for strategic planning, business development, capital market activities and related endeavors.
-
BioRestorative Therapies Receives Notice of Allowance for Key Metabolic Patent in Japan
10/17/2017
The patent will allow for a method of isolating and differentiating a non-embryonic human brown adipose-derived stem cell into functional human brown adipocytes.
-
BioRestorative Announces Published Study Of Licensed Technology To Treat Lumbar Degenerative Disc Disease
10/5/2017
-
BioRestorative Receives Notice Of Acceptance For Key Metabolic Patent In Australia
4/20/2017